
Invacare Corporation Revenue | IVC
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Invacare Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 181 M | 226 M | 851 M | 928 M | 972 M | 966 M | 1.05 B | 1.14 B | 1.27 B | 1.33 B | 1.42 B | 1.8 B | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.8 B | 181 M | 1.01 B |
Quarterly Revenue Invacare Corporation
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 165 M | - | 170 M | 189 M | 201 M | 226 M | 224 M | 226 M | 226 M | 224 M | 212 M | 196 M | 218 M | 233 M | 236 M | 236 M | 223 M | 245 M | 245 M | 246 M | 249 K | 250 M | 137 K | 49 K | 88 K | 247 M | 79 K | 74 K | 54 K | 283 M | 42 K | 42 K | 38 K | 318 M | 38 K | 331 M | 309 M | 331 M | 58 K | 74 K | 107 K | 355 M | 166 K | 143 K | 301 K | 374 M | 625 K | 279 K | 267 K |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 374 M | 38 K | 145 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | ||
|
EDAP TMS S.A.
EDAP
|
64.1 M | - | - | $ 162 M | ||
|
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M | ||
|
ShockWave Medical
SWAV
|
730 M | - | - | $ 12.3 B | ||
|
Nevro Corp.
NVRO
|
409 M | - | - | $ 217 M | ||
|
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | ||
|
Axonics Modulation Technologies
AXNX
|
366 M | - | - | $ 3.31 B | ||
|
Edwards Lifesciences Corporation
EW
|
6.07 B | $ 105.14 | -0.28 % | $ 61.5 B | ||
|
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | ||
|
ThermoGenesis Holdings
THMO
|
9.44 M | - | -25.84 % | $ 171 K | ||
|
Talis Biomedical Corporation
TLIS
|
2.13 M | - | 3.55 % | $ 7.96 M | ||
|
Abiomed
ABMD
|
1.03 B | - | - | $ 17.2 B | ||
|
Titan Medical
TMDI
|
20.1 M | - | -26.32 % | $ 19.6 M | ||
|
SmileDirectClub
SDC
|
471 M | - | -53.45 % | $ 9.71 M | ||
|
Cutera
CUTR
|
49.5 M | - | -10.19 % | $ 1.99 M | ||
|
Sientra
SIEN
|
25.1 M | - | -16.59 % | $ 10.3 M | ||
|
Acutus Medical
AFIB
|
20.2 M | - | -26.83 % | $ 2.62 M | ||
|
Smith & Nephew plc
SNN
|
4.56 B | $ 30.34 | -0.57 % | $ 26.3 B | ||
|
Viveve Medical
VIVE
|
6.43 M | - | -15.35 % | $ 1.71 M | ||
|
Penumbra
PEN
|
1.4 B | $ 320.36 | 0.39 % | $ 12.5 B | ||
|
Venus Concept
VERO
|
64.8 M | - | - | $ 726 K | ||
|
Eargo
EAR
|
37.2 M | - | - | $ 10.2 M | ||
|
Surgalign Holdings
SRGA
|
82 M | - | -32.98 % | $ 1.68 M | ||
|
BIOLASE
BIOL
|
49.2 M | - | -13.19 % | $ 166 K | ||
|
SeaSpine Holdings Corporation
SPNE
|
191 M | - | 0.28 % | $ 270 M | ||
|
Inari Medical
NARI
|
494 M | - | - | $ 4.23 B | ||
|
Viemed Healthcare
VMD
|
270 M | $ 8.81 | -2.87 % | $ 343 M | ||
|
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | ||
|
NuVasive
NUVA
|
1.2 B | - | - | $ 2.07 B | ||
|
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | ||
|
Insulet Corporation
PODD
|
2.71 B | $ 139.95 | -3.71 % | $ 9.85 B | ||
|
ViewRay
VRAY
|
102 M | - | 1.54 % | $ 468 M | ||
|
Medigus Ltd.
MDGS
|
29.9 M | - | 10.28 % | $ 55.5 M | ||
|
Vapotherm
VAPO
|
68.7 M | - | 6.72 % | $ 34 M | ||
|
Silk Road Medical, Inc
SILK
|
177 M | - | - | $ 1.07 B | ||
|
TELA Bio
TELA
|
80.3 M | $ 0.78 | 2.43 % | $ 36.6 M | ||
|
Zynex
ZYXI
|
192 M | - | - | $ 21.1 M | ||
|
TransMedics Group
TMDX
|
605 M | $ 96.58 | 2.84 % | $ 3.28 B | ||
|
Natus Medical Incorporated
NTUS
|
473 M | - | 1.94 % | $ 1.05 B | ||
|
Nemaura Medical
NMRD
|
77 K | - | -17.8 % | $ 2.74 M | ||
|
Butterfly Network
BFLY
|
97.6 M | $ 6.11 | 6.0 % | $ 1.51 B | ||
|
Zimmer Biomet Holdings
ZBH
|
8.23 B | $ 103.42 | 1.3 % | $ 20.5 B | ||
|
Abbott Laboratories
ABT
|
44.3 B | $ 104.47 | -0.23 % | $ 182 B | ||
|
Align Technology
ALGN
|
4.03 B | $ 163.89 | 0.26 % | $ 11.9 B | ||
|
Alphatec Holdings
ATEC
|
764 M | $ 7.08 | 1.95 % | $ 1.06 B | ||
|
Boston Scientific Corporation
BSX
|
20.1 B | $ 43.66 | 1.45 % | $ 64.6 B | ||
|
Cognyte Software Ltd.
CGNT
|
400 M | $ 7.93 | 1.34 % | $ 578 M | ||
|
Aethlon Medical
AEMD
|
574 K | $ 5.05 | -0.59 % | $ 3.4 M | ||
|
Bio-Rad Laboratories
BIO
|
2.58 B | $ 369.72 | 3.22 % | $ 10.1 B |